Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Good news! CSPC Pharmaceutical's semaglutide injection has completed enrollment of all cases in the Phase III clinical trial for weight management indication.
Published Time：
2024-12-03
Good news on R&D innovation. Recently, the Phase III clinical trial for the weight management indication of Semaglutide Injection developed by Lizhu Group's subsidiary, Xinbei Jiang Pharmaceutical Co., Ltd., has completed enrollment of all cases. The rapid advancement of the clinical trial has laid a solid foundation for the drug's launch.
Semaglutide Injection is a biosimilar independently developed by Lizhu Group. The indication for this clinical trial is chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/㎡ or higher (obesity) or 27 kg/㎡ or higher (overweight) and at least one weight-related comorbidity (such as hypertension, dyslipidemia, fatty liver, obstructive sleep apnea syndrome).
Semaglutide Injection obtained clinical approval for the weight management indication in February 2024 and initiated clinical trials. As a long-acting GLP-1 receptor agonist, Semaglutide Injection has the effects of lowering blood sugar, protecting the cardiovascular system, and controlling weight. Driven by application needs, its market share is continuously increasing. According to Novo Nordisk's announcement, the global sales of Semaglutide Injection and oral tablets reached US$20.59 billion in the first three quarters of this year, indicating huge market potential.
As an innovative pharmaceutical company, Lizhu Group actively responds to industry and market challenges, deeply focusing on unmet clinical needs. Driven by both independent R&D and BD, it continuously increases the innovation efforts in high-barrier complex preparations, and several key projects under development have achieved phased results. In the future, Lizhu Group's innovative achievements will be gradually realized, benefiting more patients.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.